relief solid put focu
water finish strong note deliv beat initi
guidanc bracket forecast better expect quarter conclud
softer year rel perform compani believ wednesday
stock reaction vs flat reflect weaker sentiment
print constant currenc growth exceed expect
balanc growth across product categori end market biopharma
geographi americas/asia view critic thesi alway
area nitpick result declin
quarter europ trend remain soft though headlin messag appear
posit water leverag top-lin perform deliv ep beat
vs forecast guidanc water benefit
lower-than-expect tax rate vs model well lower
share count lower forecast collect ad
quarter vs forecast
turn guidanc initi forecast broadli bracket
expect revenu compani forecast organ growth
expect similar rang fx forecast headwind
revenu growth drive total revenu year rel
compani start similar target organ growth miss
deliv organ believ contribut strong new product cadenc
improv visibl target adj ep forecast
repres growth y/i part new billion repurchas plan
embed billion share repurchas guidanc encourag
compani acceler plan deploy capit view current valuat
appropri adj ebitda context compani growth
outlook reiter equal weight rate
quarterli annual ep usd
consensu number thomson reuter receiv gmt
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
rais usd
return equiti ttm
link barclay live interact chart
equal weight admir track
record above-market revenu growth margin
given compani market domin
pharmaceut custom chromatographi
said balanc water success view
difficult gener sustain above-
market earn growth reflect
biopharma remain area strength higher
consum margin drive upsid
ebitda expect upsid ebitda
million yield upsid case
fund biotech pressur capit invest
life scienc tool drive downsid
ebitda estim downsid ebitda
million yield downsid case
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
water finish strong note deliv beat initi guidanc
bracket forecast better expect quarter conclud softer year
rel perform compani believ wednesday stock reaction
vs flat reflect weaker sentiment print constant
currenc growth exceed expect balanc growth
across product categori
end market biopharma geographi
americas/asia view critic thesi alway
area nitpick result water industri declin quarter
europ trend remain soft though headlin messag appear posit water
leverag top-lin perform deliv ep beat vs forecast
guidanc water benefit lower-than-expect
tax rate vs model well lower share count
lower forecast collect ad quarter vs forecast
turn guidanc initi forecast broadli bracket
expect revenu compani forecast organ growth
expect similar rang fx forecast headwind revenu
growth drive total revenu year rel
compani start similar target organ growth miss deliv
organ believ contribut strong new product cadenc improv
visibl target adj ep forecast repres
growth y/i part new billion repurchas plan embed billion
share repurchas guidanc encourag compani
acceler plan deploy capit view current valuat appropri
adj ebitda context compani growth outlook reiter
rais price target given increas visibl new product
contribut increment better end market trend pt repres
adjust ebitda million prior price target repres
prior adjust ebitda forecast million
water issu guidanc bracket expect revenu
ep revenu compani forecast organ growth fx headwind
lead total revenu growth gross margin expect
line level net interest expens expect approxim
million million increas result increment debt relat
compani new leverag target net debt-to-ttm ebitda quarter
water announc new billion expand repurchas plan expect
execut upon next two year guidanc assum billion repurchas
includ million would bring compani weight
averag share count million tax anticip non-gaap tax rate
repres increas midpoint guidanc call
ep rang repres growth y/i foreign
exchang expect headwind ep
guid toward organ revenu growth headwind
fx impli total revenu growth ep expect rang
fx expect headwind ep addit
guidanc
anticip increas tax rate due discret item occur
revenu million expect million
constant currenc growth better expect model
midpoint manag guidanc revenu repres
growth y/i ex-fx total growth fx headwind compar
compani guidanc million embed organ growth
fx headwind note benefit addit workday quarter
could benefit recur revenu underli growth across product
segment stronger quarter rel result first month
year instrument y/i ex-fx recur revenu grew y/i ex-
fx includ growth servic chemistri improv chemistri
growth reassur see unusu soft result
continu believ tax reform net posit
compani gain access signific amount oversea cash remind
compani capit deploy prioriti includ invest busi optim
compani balanc sheet return capit sharehold compani quickli
made progress deploy capit toward prioriti
intern invest compani announc million invest
precis chemistri facil massachusett invest expect
spread next five year million spend expect
 acquir prosolia desi technolog juli million
term return capit sharehold announc new share
repurchas author earn board author billion
repurchas two year billion expect complet
embed guidanc includ million expect complet
water repurchas share result billion total
repurchas compani establish new target leverag net
revenueorgan growth adj day barclay corp
oversea
end market perspect biopharma full-year sale end market
deliv ex-fx growth improv strength china
us partial off-set soft europ india compani optimist
recent trend ms note high resolut ms perform well quarter
industri full-year sale end market grew ex-fx y/i deceler
ta grew ex-fx within impli legaci lag
perform final academ full-year sale end market grew ex-fx
y/i compar organ growth similar comp
water note strength drug discoveri applic partial off-set demand
biomed research weak third consecut quarter remind
segment volatil good read-through coverag given
greater instrument exposur govern exposur within custom
total thousandscash oversea total oversea barclay corp
growth across geograph end market mix asia drove result
growth y/i ex-fx america increas y/i ex-fx europ declin
ex-fx asia growth driven china y/i result india
modest expect europ pharma growth off-set weak
industri academ end market america us grew broad-bas
strength includ pickup spend larg pharma compani
water geograph divers rev
water revenu breakdown end market
post stronger expect quarter biopharma organ
growth forecast compani post strength china
organ growth improv modest growth europ roughli
flat growth india experienc steadi trend across small molecul custom
biopharma exposur robust trend larg molecul custom
confer call water ceo chri oconnel note fourth quarter sale
broadly-defin pharmaceut categori increas year-over-year driven double-
digit growth china aforement pickup unit state partial off-set
expect soft european indian pharma market importantli demand
lc product line remain strong outsid market-rel pocket weak europ
india
tool average includ agil thermo fisher
academ govern busi grew y/i organ quarter
strength drug discoveri applic partial off-set demand biomed
research weak third consecut quarter geograph basi healthi
academ trend asia partial off-set softer trend europ america
import rememb academ govern segment
lumpi gener great read-through peer factor point
compar academic/govern exposur peer
import rememb academ govern segment
lumpi gener great read-through peer factor point
compar academic/govern exposur peer
mix academic/govern exposur broader mani
peer compani nih busi also dod fbi usda
name gener nih repres academ govern revenu
remaind coverag
academ govern smallest custom class repres
total revenu gener academic/govern custom major util
chromatographi system also mean percentag revenu
consum servic stream lower area instead sale gener
driven high-end mass spectrometri placement lumpi quarterli
basi chromatographi largest product segment monitor
biopharma trend better read segment perform addit
natur market academ govern notabl sticki
trend tend vari per quarter
similarli less consum revenu academic/govern
custom class peer water broad consum stream lab
suppli sampl prep like thermo fisher agil drive consist
govern academ exposur
end market perform quarter
revenu grew organ ta instrument
water divis revenu growth ex-fx y/i water divis
revenu million came million expect
million increas y/i organ basi revenu increas y/i
estim chemistri revenu exceed organ expect
versu expect organ instrument revenu
segment expect growth instrument
market y/i y/i growth y/i y/i growth y/i y/i growth y/i growth barclay corp
growth driven compani liquid chromatographi lc portfolio servic
revenu increas organ compar model currenc
headwind segment revenu quarter versu forecast
management guidanc headwind
ta instrument divis revenu growth ex-fx y/i ta instrument
revenu million came million estim increas
organ y/i versu forecast organ currenc headwind
quarter versu estim headwind
water revenu segment million
non-gaap ep increas y/i buoy better expect
oper margin lower tax rate vs forecast modestli
lower share count note ep came high end manag guidanc
 compani share count came expect ad
ep rel model lower tax rate ad result adjust ep
came meaning higher estim
water non-gaap ep growth
gross margin came expect compani
attribut quarter-specif mix gross margin y/i full year
compani previous guid investor gross margin flat
y/i perform report gross margin came
high end rang expect gross margin
line
water gross margin adjust ebitda
sg ex-stock comp expens y/i revenu
 expens total revenu y/i model
rel steadi expenditur compani continu invest intern growth
water adjust sg trend
adjust oper incom million grew y/i came
forecast oper margin y/i
estim better expect gross margin lower expect
total sg includ stock comp drove beat
percentag revenu come line estim
water ebit margin annual growth
deliv million cffo forecast exclud
million relat settlement pension plan million
relat invest tandem precis chemistri oper compani
activ share repurchas repurchas share model
author valid two-year period replac previou author
result tax reform compani increas access oversea cash
believ could result acceler capit deploy activ pleas see
observ two detail
water use oper million
 mm except ep reportedincom growth profit ebitda ebit debt pre-tax pre-tax tax net adj net researchprior yearprior quarter barclay corp
estestestestestestestestincom statement growth growth growth growth growth growth y/i growth y/i organ adj growth product product product revenu inc product revenu inc servic servic gross gross margin inc gross margin inc growth growth y/i administr growth growth y/i base sg stock base oper growth growth y/i ebitda growth acquir intang oper incom ebit growth debt invest pre-tax pre-tax growth benefit incom tax net net growth adj adj barclay corp
meehan cfa herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens directli indirectli relat
specif recommend view express research report
